In a striking moment during Germany's ongoing Corona Inquiry Commission (Enquete-Kommission) on 19 March 2026, Dr. Helmut Sterz, former Chief Toxicologist for Pfizer Europe, delivered blunt testimony that has reignited debate over the approval and rollout of Pfizer's Comirnaty mRNA COVID-19 vaccine.
With decades of experience in pharmaceutical toxicology, including responsibility for animal safety studies at Pfizer, Sterz told parliamentarians that essential long-term safety testing was skipped and that the vaccine never should have received regulatory approval under normal standards.
Dr. Sterz's Core Argument
Sterz's central claim is straightforward and damning from a toxicologist's perspective:
"The Pfizer vaccine should never have been approved."
He argued that the accelerated approval process was only justifiable for an extremely lethal pathogen, such as Ebola. Treating a virus with severity comparable to seasonal influenza as an emergency requiring rushed development led to what he called a "vaccination tragedy" with millions of victims worldwide.
Key points from his testimony and submitted statement:
Inadequate Toxicology Studies: Standard long-term safety assessments, including proper carcinogenicity (cancer risk) testing, were not conducted due to "time constraints." Sterz described this as "regrettable" and noted that no adequate alternative investigations were performed.
Insufficient Reproductive and Fertility Testing: Proper studies on the vaccine's impact on pregnancy and fertility were also lacking or inadequate.
Skipped Animal Safety Protocols: As the former head responsible for animal experiments serving drug safety at Pfizer Europe, Sterz stated that critical toxicological evaluations were sacrificed to speed. He described elements of the process as "simulated" or insufficient for a mass-administered product given to billions.
Scale of Harm: Sterz estimated that vaccine-related deaths in Germany alone could be near 60,000, applying an under-reporting factor of around 30 (commonly referenced in U.S. vaccine adverse event analysis). He views the overall rollout as having caused widespread harm.
Sterz emphasised that for a pharmaceutical product injected into healthy people on such a massive scale, normal rigorous safety standards must apply. Expedited procedures appropriate for a genuine existential threat were wrongly applied to COVID-19.
Context of the Testimony
Dr. Sterz was appearing as an expert witness before the Bundestag's formal inquiry into Germany's COVID-19 response. His comments align with growing scrutiny in several countries over the speed of mRNA vaccine development, the limited duration of clinical trials, and post-approval safety signals.
Official bodies such as the European Medicines Agency (EMA) and Germany's Paul-Ehrlich-Institute continue to maintain that the vaccines met the safety standards applicable at the time and that benefits outweighed risks, including rare side effects. Of couse they would.
Dr. Sterz is not an outsider or critic from the beginning. He is a career toxicologist who worked inside the system at Pfizer Europe. His insider critique carries weight precisely because it comes from someone who understands the normal drug development and safety evaluation process.
His testimony raises fundamental questions that go beyond any single vaccine:
Should emergency-use standards for novel platforms like mRNA be applied to products given to hundreds of millions of healthy adults and children?
How much long-term safety data is ethically required before mass deployment?
What accountability mechanisms exist when expedited approvals later show gaps in safety evaluation?
For many who have questioned aspects of the COVID response, from lockdowns to vaccine mandates, Sterz's statements provide validation that concerns about rushed science and inadequate testing were not baseless conspiracy theories but legitimate scientific and regulatory issues.
This hearing is part of a slowly unfolding international reckoning. Similar inquiries in other countries, along with growing volumes of pharmacovigilance data, continue to examine excess mortality trends, fertility signals, and reported adverse events following the mass vaccination campaign.
Dr. Sterz's conclusion is uncompromising: the combination of insufficient toxicology, skipped long-term studies, and an approval process mismatched to the actual threat level made the rollout irresponsible. In his view, the result has been unnecessary harm on a large scale.
Whether one agrees with every aspect of his assessment or not, his testimony underscores a vital principle: public health measures, especially those involving new medical technologies administered to entire populations, demand the highest standards of evidence and caution, not shortcuts justified by panic or political pressure.
The German Bundestag inquiry continues. Dr. Sterz's evidence adds a significant voice from inside the pharmaceutical industry to the growing historical record of the COVID era.